BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 235 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.62 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $21,420 | +19.1% | 1,700 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $17,986 | -34.9% | 1,700 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $27,642 | +17.4% | 1,700 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $23,545 | -95.5% | 1,700 | -95.4% | 0.00% | -95.0% |
| Q3 2021 | $527,379 | -9.8% | 36,700 | -0.8% | 0.02% | -13.0% |
| Q2 2021 | $584,970 | +59.1% | 37,000 | +2.4% | 0.02% | +43.8% |
| Q1 2021 | $367,646 | +166.7% | 36,150 | +95.4% | 0.02% | +128.6% |
| Q4 2020 | $137,825 | +2181.1% | 18,500 | +951.7% | 0.01% | – |
| Q3 2020 | $6,042 | +26.8% | 1,759 | +75.9% | 0.00% | – |
| Q2 2020 | $4,765 | – | 1,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |